| Preview
Full Doc
 | 2002 |
Development and Commercialization Agreement
Development and Commercialization Agreement (320K)
Doc #140457: Click preview link for longer preview.
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [ * ]. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission.
{PAGE}
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
ARTICLE 1 DEFINITIONS2
1.1. "ACLARA COMPONENT" ..................................... 2
1.2. "ACLARA MARKS" ......................................... 2
1.3. "ACLARA PARTNER" ....................................... 2
1.4. "ACLARA TECHNOLOGY" .................................... 2
1.5. "AFFILIATE" ............................................ 2
1.6. "APPROVED PRODUCT" ..................................... 3
1.7. "[ * ] INSTRUMENT" ..................................... 3
1.8. "CLEAVASE ENZYME" ...................................... 3
1.9. "COLLABORATION PRODUCT" ................................ 3
1.10. "COMMERCIAL LAUNCH" .................................... 3
1.11. "COMMERCIALIZATION COSTS" .............................. 3
1.12. "COMMERCIALIZING PARTY" ................................ 4
1.13. "COMMERCIALIZATION PLAN AND BUDGET" .................... 4
1.14. "COMMERCIALIZATION TEAM LEADER" ........................ 4
1.15. "CONTROLLED AFFILIATE" ................................. 4
1.16. "COVER" ................................................ 4
1.17. "CUSTOMER" ............................................. 4
1.18. "DEVELOPMENT COMMITTEE" ................................ 4
1.19. "DEVELOPMENT COSTS" .................................... 4
1.20. "DEVELOPMENT PERSONNEL" ................................ 4
1.21. "DEVELOPMENT PLAN AND BUDGET" .......................... 4
1.22. "DEVELOPMENT PROGRAM" .................................. 5
1.23. "DEVELOPMENT RATE" ..................................... 5
1.24. "DEVELOPMENT TERM" ..................................... 5
1.25. [ * ] .................................................. 5
1.26. "EARLY ACCESS PROGRAM" ................................. 5
1.27. "ETAG PRODUCT" ......................................... 5
1.28. "ETAG SIGNAL PROBE" .................................... 5
1.29. "EXCLUSIVE CONTROL" .................................... 5
1.30. "EXCLUSIVE TARGET ROYALTY" ............................. 5
1.31. "FIELD" ................................................ 5
1.32. "FINANCE SUB-COMMITTEE" ................................ 6
1.33. "FTE" OR "FULL-TIME EQUIVALENT" ........................ 6
1.34. "GAAP" ................................................. 6
1.35. "GENOTYPING APPLICATIONS" .............................. 6
1.36. "INTELLECTUAL PROPERTY RIGHTS" ......................... 6
1.37. "INTELLECTUAL PROPERTY SUB-COMMITTEE" .................. 6
1.38. "INVADER PROBE" ........................................ 6
-i-
{PAGE}
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
1.39. "INVADER REACTION" ..................................... 6
1.40. "JOINT DISTRIBUTOR" .................................... 6
1.41. "JOINT MARK" ........................................... 6
1.42. "JOINT PRODUCT FORECAST" ............................... 7
1.43. "JOINT STEERING COMMITTEE" ............................. 7
1.44. "LICENSABLE" ........................................... 7
1.45. "MANUFACTURING COSTS" .................................. 7
1.46. "MANUFACTURING PARTY" .................................. 7
1.47. "MARKETING DISTRIBUTOR" ................................ 8
1.48. [ * ] .................................................. 8
1.49. "MILESTONE" ............................................ 8
1.50. "MULTI-TARGET ANALYSIS" ................................ 8
1.51. "MULTI-TARGET ETAG PROBE SET" .......................... 8
1.52. "NET SALES" ............................................ 8
1.53. "NON-COMMERCIALIZING PARTY" ............................ 9
1.54. "NON-EXCLUSIVE CONTROL" ................................ 9
1.55. "NON-EXCLUSIVE TARGET ROYALTY" ......................... 9
1.56. "NON-HYBRIDIZING REGION" ............................... 9
1.57. "PATENT RIGHTS" ........................................ 9
1.58. "PRIMARY PROBE" ........................................ 9
1.59. "PROJECT LEADER" ....................................... 10
1.60. "PROPRIETARY TARGET ROYALTY" ........................... 10
1.61. [ * ] .................................................. 10
1.62. "SALES GOAL" ........................................... 10
1.63. "SOFTWARE" ............................................. 10
1.64. "SPECIFICATIONS" ....................................... 10
1.65. "TARGET" ............................................... 11
1.66. "TARGET FEES" .......................................... 11
1.67. "TECHNOLOGY" ........................................... 11
1.68. "TWT TECHNOLOGY" ....................................... 11
1.69. "TWT MARKS" ............................................ 11
1.70. "VALID CLAIM" .......................................... 11
ARTICLE 2 DEVELOPMENT PROCEDURES ......................................... 12
2.1. PROJECT LEADERS ........................................ 12
2.2. DEVELOPMENT COMMITTEE .................................. 13
ARTICLE 3 DEVELOPMENT PLAN AND BUDGET .................................... 14
3.1. GENERAL ................................................ 14
3.2. CONTENTS ............................................... 15
3.3. PERIODIC REVIEWS ....................................... 15
3.4. DEVELOPMENT PRIORITIES ................................. 15
-ii-
{PAGE}
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
3.5. EXPANSION OF THE FIELD ................................. 15
ARTICLE 4 DEVELOPMENT PROGRAM ............................................ 15
4.1. DEVELOPMENT PROGRAM .................................... 15
4.2. [ * ] INSTRUMENTS ...................................... 16
4.3. PROPRIETARY TARGETS .................................... 16
4.4. CHANGES ................................................ 18
4.5. EXTENSION OF MILESTONE DATES ........................... 18
4.6. DEVELOPMENT REPORTS AND RECORDS ........................ 18
4.7. DEVELOPMENT TERM ....................................... 19
4.8. DEVELOPMENT PROGRAM LICENSES ........................... 19
4.9. THIRD PARTY TECHNOLOGY ................................. 19
4.10. AGREEMENTS WITH EMPLOYEES AND SUBCONTRACTORS ........... 20
4.11. VISITING PERSONNEL ..................................... 20
4.12. EQUIPMENT OWNERSHIP .................................... 20
ARTICLE 5 FUNDING OF DEVELOPMENT PROGRAM ................................. 20
5.1. FUNDING ................................................ 20
5.2. DEVELOPMENT RATE ....................................... 20
5.3. OTHER APPROVED DEVELOPMENT COSTS ....................... 21
5.4. PAYMENT ................................................ 21
5.5. EXCESS COSTS ........................................... 21
5.6. RECONCILIATION ......................................... 22
ARTICLE 6 JOINT STEERING COMMITTEE AND COMMERCIALIZATION PLAN
AND BUDGET ..................................................... 22
6.1. GENERAL ................................................ 22
6.2. COMMERCIALIZATION TEAM LEADER .......................... 22
6.3. [INTENTIONALLY OMITTED] ................................ 23
6.4. JOINT STEERING COMMITTEE ............................... 23
6.5. FINANCE SUB-COMMITTEE .................................. 25
6.6. COMMERCIALIZATION PLAN AND BUDGET ...................... 25
6.7. FUNDING OF COMMERCIALIZATION ACTIVITIES ................ 27
6.8. JOINT PRODUCT FORECASTS AND ORDERS ..................... 29
ARTICLE 7 COMMERCIALIZATION .............................................. 29
7.1. GENERAL RESPONSIBILITIES ............................... 29
7.2. SALES GOALS ............................................ 30
7.3. COMMERCIAL LAUNCH ...................................... 30
7.4. MARKETING AND DISTRIBUTION BY TWT ...................... 30
7.5. MARKETING AND DISTRIBUTION BY ACLARA ................... 31
7.6. INDIRECT DISTRIBUTION .................................. 31
7.7. NO OTHER DISTRIBUTION RIGHTS ........................... 32
-iii-
{PAGE}
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
7.8. PRODUCT CONFIGURATIONS ................................. 32
7.9. MARKETING MATERIALS AND PRESENTATIONS .................. 32
7.10. CUSTOMER AGREEMENTS .................................... 32
7.11. THIRD PARTY PATENTS .................................... 33
7.12. PACKAGING AND LABELING ................................. 33
7.13. CUSTOMER RESTRICTIONS .................................. 34
7.14. CUSTOMER SUPPORT AND WARRANTIES ........................ 34
7.15. INTERNAL USE ........................................... 34
ARTICLE 8 COMMERCIALIZATION ECONOMICS .................................... 35
8.1. INITIAL PAYMENTS ....................................... 35
8.2. ACCOUNTING DEFINITIONS ................................. 35
8.3. ACCOUNTING BASED ON SALES .............................. 36
8.4. PROPRIETARY TARGET ROYALTIES ........................... 37
8.5. PROPRIETARY TARGET OFFSETS ............................. 38
8.6. BUNDLING ............................................... 39
8.7. OTHER THIRD PARTY ROYALTIES ............................ 39
ARTICLE 9 TRADEMARKS AND BRANDING ........................................ 39
9.1. JOINT MARKS ............................................ 39
9.2. CO-BRANDING ............................................ 40
ARTICLE 10 MANUFACTURING ................................................. 42
10.1. LICENSES ............................................... 42
10.2. RESTRICTIONS ........................................... 42
10.3. RESPONSIBILITIES ....................................... 42
10.4. ECONOMICS .............................................. 43
10.5. PRODUCT CHANGES ........................................ 43
ARTICLE 11 SUPPLY OF ACLARA COMPONENTS ................................... 44
11.1. TERMS AND CONDITIONS ................................... 44
11.2. SUPPLY ................................................. 44
11.3. FORECASTS .............................................. 44
11.4. ORDERS ................................................. 45
11.5. COMPENSATION ........................................... 45
11.6. DELIVERY ............................................... 45
11.7. INVOICING .............................................. 46
11.8. QUALITY AND QUALITY CONTROL ............................ 46
11.9. INSPECTION/REJECTION ................................... 46
11.10. PRODUCT WARRANTY ....................................... 47
11.11. SHORTAGE OF SUPPLY OF ACLARA COMPONENTS ................ 47
11.12. THIRD PARTY CONTRACTORS ................................ 50
-iv-
{PAGE}
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
ARTICLE 12 SUPPLY OF APPROVED PRODUCTS ................................... 50
12.1. TERMS AND CONDITIONS ................................... 50
12.2. SUPPLY ................................................. 50
12.3. FORECASTS .............................................. 51
12.4. ORDERS ................................................. 52
12.5. CONSIDERATION .......................................... 52
12.6. DELIVERY ............................................... 53
12.7. INVOICING .............................................. 53
12.8. QUALITY AND QUALITY CONTROL ............................ 53
12.9. INSPECTION/REJECTION ................................... 53
12.10. PRODUCT WARRANTY ....................................... 54
12.11. SHORTAGE OF SUPPLY OF APPROVED PRODUCTS ................ 54
12.12. THIRD PARTY CONTRACTORS ................................ 58
ARTICLE 13 PAYMENTS; REPORTS; RECORDS .................................... 59
13.1. RECONCILIATION ......................................... 59
13.2. INITIAL PAYMENT UPON MANUFACTURE OF APPROVED
PRODUCTS ............................................... 59
13.3. SUPPLY OF ACLARA COMPONENTS AND APPROVED PRODUCTS
TO TWT ................................................. 59
13.4. SUPPLY OF CLEAVASE ENZYME AND APPROVED PRODUCTS
TO ACLARA .............................................. 59
13.5. PAYMENTS FOR INTERNAL USE BY THE MANUFACTURING
PARTY .................................................. 59
13.6. PAYMENT METHOD ......................................... 60
13.7. CURRENCY CONVERSION .................................... 60
13.8. RECORDS; INSPECTION .................................... 60
13.9. TAXES .................................................. 61
ARTICLE 14 INTELLECTUAL PROPERTY ......................................... 62
14.1. OWNERSHIP .............................................. 62
14.2. PROSECUTION OF SOLELY OWNED PATENT RIGHTS .............. 64
14.3. PROSECUTION OF JOINTLY OWNED PATENT RIGHTS ............. 64
ARTICLE 15 CONFIDENTIALITY ............................................... 66
15.1. CONFIDENTIAL INFORMATION ............................... 66
15.2. PERMITTED USE AND DISCLOSURE ........................... 67
15.3. CONFIDENTIAL TERMS/PUBLICITY ........................... 67
15.4. PROPRIETARY MARKINGS ................................... 67
ARTICLE 16 REPRESENTATIONS, WARRANTIES, AND DISCLAIMERS .................. 68
16.1. GENERAL ................................................ 68
16.2. BY TWT ................................................. 68
16.3. BY ACLARA .............................................. 68
16.4. DISCLAIMERS ............................................ 68
-v-
{PAGE}
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
ARTICLE 17 INDEMNIFICATION ............................................... 69
17.1. INDEMNIFICATION OF TWT ................................. 69
17.2. INDEMNIFICATION OF ACLARA .............................. 70
17.3. PROCEDURE .............................................. 70
ARTICLE 18 DISPUTE RESOLUTION ............................................ 71
18.1. DISPUTES ............................................... 71
18.2. FULL ARBITRATION ....................................... 71
18.3. SHORT FORM ARBITRATION ................................. 72
18.4. COMMERCIALIZATION PLAN AND BUDGET DISPUTE
RESOLUTION ............................................. 73
ARTICLE 19 TERM AND TERMINATION .......................................... 74
19.1. TERM ................................................... 74
19.2. NO APPROVAL FOR COMMERCIAL LAUNCH ...................... 74
19.3. TERMINATION FOR CAUSE .................................. 74
19.4. [INTENTIONALLY OMITTED] ................................ 75
19.5. EFFECT OF TERMINATION .................................. 75
ARTICLE 20 GENERAL ....................................................... 80
20.1. NO OTHER RIGHTS ........................................ 80
20.2. GOVERNING LAW AND JURISDICTION ......................... 80
20.3. ASSIGNMENT ............................................. 80
20.4. INDEPENDENT CONTRACTORS ................................ 81
20.5. FORCE MAJEURE .......................................... 81
20.6. NOTICES ................................................ 81
20.7. COMPLIANCE WITH LAWS ................................... 82
20.8. ARTICLE AND SECTION HEADINGS, LANGUAGE AND
CONSTRUCTION ........................................... 82
20.9. MODIFICATION AND WAIVER ................................ 82
20.10. SEVERABILITY ........................................... 83
20.11. ENTIRE AGREEMENT ....................................... 83
20.12. FURTHER ASSURANCES ..................................... 83
20.13. BANKRUPTCY ............................................. 84
20.14. COUNTERPARTS ........................................... 84
-vi-
{PAGE}
CONFIDENTIAL
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Development and Commercialization Agreement (the "AGREEMENT"),
effective as of October 24, 2001 (the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc., a Delaware corporation, having a place of business at 1288 Pear Avenue,
Mountain View, CA 94043 ("ACLARA") (each a "PARTY;" together the "PARTIES").
BACKGROUND
A. TWT has technology and intellectual property for, among other
things, genetic analysis, including test kits, components, and other products
and services based upon its proprietary Invader(R) platform, and is in the
business of manufacturing and commercializing such products, components and
services.
B. Similarly, ACLARA has technology and intellectual property for,
among other things, genetic analysis and biopharmaceutical research, including
products and components based upon ACLARA's proprietary eTag(TM) technology.
C. On the terms and conditions set forth below, ACLARA and TWT desire
to collaborate to develop and commercialize assay kits for use on [ * ]
instruments commercially available from third parties to perform simultaneous
multiple gene expression and/or genotyping assays, each assay testing for a
unique analyte, using ACLARA's eTag(TM) technology in TWT's Invader(R) platform.
D. Additionally, TWT has built up significant manufacturing capacities
and capabilities for assay kits which the Parties intend to utilize, to the
extent mutually agreed, to manufacture the co-developed assay products
hereunder, all on the terms and conditions set forth below.
E. The Parties acknowledge that the arrangement set forth in this
Agreement is intended to make available to customers a wider range and variety
of products than would have been available in the time frames contemplated
herein in the absence of the collaboration between the Parties.
NOW, THEREFORE, for and in consideration of the covenants, conditions
and undertakings hereinafter set forth, TWT and ACLARA each agree as follows:
140457
|
ACLARA
As referenced in this Development and Commercialization Agreement:
ACLARA BIOSCIENCES, INC. – 10.29
{SEQUENCE}8
{FILENAME}dex1029.txt
{DESCRIPTION}DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
{TEXT}
{PAGE}
EXHIBIT 10.29
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated
_____________
ACLARA BioSciences,
Inc. – the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc. , a Delaware corporation, having a place of business at 1288 Pear Avenue,
Mountain View, CA 94043 ("ACLARA") (each a "PARTY;" together the "PARTIES").
BACKGROUND
A. TWT has technology and
_____________
ACLARA BioSciences, Inc. – following address or such other address as may from time to
time be designated to the other Party in writing in accordance with this Section
20.6:
If to: ACLARA
ACLARA BioSciences, Inc.
1288 Pear Avenue
Mountain View, CA 94043
Attn: President and CEO
Telefax: (650) 210-9271
-81-
{PAGE}
CONFIDENTIAL
With a copy to:
Vice President, Legal Affairs
If to: TWT
_____________
ACLARA BIOSCIENCES, INC. – and the same instrument.
[Intentionally Left Blank]
-84-
{PAGE}
CONFIDENTIAL
IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Agreement.
THIRD WAVE TECHNOLOGIES, INC. ACLARA BIOSCIENCES, INC.
("TWT") ("ACLARA")
{TABLE}
{CAPTION}
{S} {C} {C} {C}
By: /s/ Ian B. Edvalson By: /s/ Philip A. Petersen
---------------------------------- -------------------------------------
Name: IAN B. EDVALSON Name: PHILIP A. PETERSEN
---------------------------------- -------------------------------------
Title: SR VP,
_____________
dt 1453637
;
ACLARA
As referenced in this Development and Commercialization Agreement:
ACLARA BIOSCIENCES, INC. – 10.29
{SEQUENCE}8
{FILENAME}dex1029.txt
{DESCRIPTION}DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
{TEXT}
{PAGE}
EXHIBIT 10.29
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated
_____________
ACLARA BioSciences,
Inc. – the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc. , a Delaware corporation, having a place of business at 1288 Pear Avenue,
Mountain View, CA 94043 ("ACLARA") (each a "PARTY;" together the "PARTIES").
BACKGROUND
A. TWT has technology and
_____________
ACLARA BioSciences, Inc. – following address or such other address as may from time to
time be designated to the other Party in writing in accordance with this Section
20.6:
If to: ACLARA
ACLARA BioSciences, Inc.
1288 Pear Avenue
Mountain View, CA 94043
Attn: President and CEO
Telefax: (650) 210-9271
-81-
{PAGE}
CONFIDENTIAL
With a copy to:
Vice President, Legal Affairs
If to: TWT
_____________
ACLARA BIOSCIENCES, INC. – and the same instrument.
[Intentionally Left Blank]
-84-
{PAGE}
CONFIDENTIAL
IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Agreement.
THIRD WAVE TECHNOLOGIES, INC. ACLARA BIOSCIENCES, INC.
("TWT") ("ACLARA")
{TABLE}
{CAPTION}
{S} {C} {C} {C}
By: /s/ Ian B. Edvalson By: /s/ Philip A. Petersen
---------------------------------- -------------------------------------
Name: IAN B. EDVALSON Name: PHILIP A. PETERSEN
---------------------------------- -------------------------------------
Title: SR VP,
_____________
dt 1463872
;
|
Third Wave
As referenced in this Development and Commercialization Agreement:
THIRD WAVE TECHNOLOGIES, – SEQUENCE}8
{FILENAME}dex1029.txt
{DESCRIPTION}DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
{TEXT}
{PAGE}
EXHIBIT 10.29
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed
_____________
Third Wave Technologies, – COMMERCIALIZATION AGREEMENT
This Development and Commercialization Agreement (the "AGREEMENT"),
effective as of October 24, 2001 (the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc.,
_____________
Third Wave Technologies, – 94043
Attn: President and CEO
Telefax: (650) 210-9271
-81-
{PAGE}
CONFIDENTIAL
With a copy to:
Vice President, Legal Affairs
If to: TWT
Third Wave Technologies, Inc.
502 South Rosa Road
Madison, WI 53719
Attn: President
Telefax: (608) 273-8618
With a copy to:
Wilson Sonsini Goodrich & Rosati
_____________
THIRD WAVE TECHNOLOGIES, – instrument.
[Intentionally Left Blank]
-84-
{PAGE}
CONFIDENTIAL
IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Agreement.
THIRD WAVE TECHNOLOGIES, INC. ACLARA BIOSCIENCES, INC.
("TWT") ("ACLARA")
{TABLE}
{CAPTION}
{S} {C} {C} {C}
By: /s/ Ian B. Edvalson By: /s/ Philip A. Petersen
---------------------------------- -------------------------------------
_____________
Third Wave Technologies, – Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
{PAGE}
CONFIDENTIAL
EXHIBIT 1.69
TWT MARKS
o Third Wave Technologies, Inc.
o Invader(R)
o Cleavase(R)
{PAGE}
CONFIDENTIAL
EXHIBIT 3.1
INITIAL DEVELOPMENT PLAN AND BUDGET
INITIAL WORK PLAN
[ * ]
---------------------
[ * ] Certain information
_____________
dt 130359
;
 WSGR
As referenced in this Development and Commercialization Agreement:
Wilson Sonsini – Rosa Road
Madison, WI 53719
Attn: President
Telefax: (608) 273-8618
With a copy to:
Wilson Sonsini Goodrich & Rosati
650 Page Mill Road
Palo Alto, CA 94304-1050
Attn: Kenneth A.
dt 30850
|
| Preview
Full Doc
| 2001 |
Joint Development & Commercialization Agreement
Joint Development & Commercialization Agreement (196K)
Doc #140478: Click preview link for longer preview.
JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Joint Development and Commercialization Agreement ("Agreement") dated as of
the 16th day of July, 2001 ("Effective Date") is by and between deCODE GENETICS,
ehf., an Icelandic corporation, located at Hlioarsmari 15, 200 Kopavogur,
Iceland ("deCODE"), and PE CORPORATION (NY), a New York corporation, through its
Applied Biosystems Group, located at 850 Lincoln Centre Drive, Foster City, CA
94404 ("ABG").
BACKGROUND
A. ABG has certain skills, proprietary technology and know-how
related to the development of bioanalytical instrumentation systems including
associated software and reagents, and the marketing, sales and support of
products incorporating such systems.
B. deCODE has certain skills, proprietary technology and know-how
related to the operation and management of large scale genotyping facilities,
including particular expertise in the development of software to manage and
analyze data generated by such facilities.
C. deCODE and ABG desire to form a joint development and
commercialization program with the objective of developing and commercializing
software products for the collection, organization and analysis of genotyping
information subject to the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing premises and the
mutual promises and covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, do hereby agree as follows:
AGREEMENT
1. DEFINITIONS
1.1 "ABG Instrumentation" means instrumentation developed or
marketed by ABG.
1.2 "ABG API" means APIs provided to deCODE by ABG that provide
access to the functional capabilities within ABG software,
including, but not limited to, the ABG LIMS System, which is
necessary to access data necessary for the operation of a
Collaboration Product, including, but not limited to: sample
management, container management, location management,
genotype marker management, genotype assay management, and
genotype results management.
140478
|
Applied
As referenced in this Joint Development & Commercialization Agreement:
Applied Biosystems Group, – Effective Date") is by and between deCODE GENETICS,
ehf., an Icelandic corporation, located at Hlioarsmari 15, 200 Kopavogur,
Iceland ("deCODE"), and PE CORPORATION (NY), a New York corporation, through its
Applied Biosystems Group, located at 850 Lincoln Centre Drive, Foster City, CA
94404 ("ABG").
BACKGROUND
A. ABG has certain skills, proprietary technology and know-how
related to the development of bioanalytical instrumentation
_____________
APPLIED BIOSYSTEMS GROUP
– Page Follows]
41
{PAGE} 43
EXECUTION COPY
The Parties , through their authorized officers, have executed this Agreement as
of the Effective Date.
deCODE GENETICS, ehf. PE CORPORATION (NY), THROUGH
ITS APPLIED BIOSYSTEMS GROUP
By: /s/ Kari Stefansson By: /s/ Michael W. Hunkapiller
-------------------------------- ---------------------------
Name: Kari Stefansson Name: Michael W. Hunkapiller
-------------------------------- -------------------------
Title: CHIEF EXECUTIVE OFFICER Title: Senior Vice President
-------------------------------- and President Applied
Biosystems Group
------------------------
_____________
Applied
Biosystems Group
– ITS APPLIED BIOSYSTEMS GROUP
By: /s/ Kari Stefansson By: /s/ Michael W. Hunkapiller
-------------------------------- ---------------------------
Name: Kari Stefansson Name: Michael W. Hunkapiller
-------------------------------- -------------------------
Title: CHIEF EXECUTIVE OFFICER Title: Senior Vice President
-------------------------------- and President Applied
Biosystems Group
------------------------
Date: July 16, 2001 Date: July 16, 2001
-------------------------------- -------------------------
42
{PAGE} 44
EXECUTION COPY
EXHIBIT A
SOFTWARE COMPONENTS
The following describes the division of Existing deCODE Genotyping Software into
independently
_____________
Applied Biosystems Group – B
PREFERRED SOFTWARE ESCROW AGREEMENT
Account Number
------------------------
This Agreement is effective __________________, 2001 among DSI Technology Escrow
Services, Inc. ("DSI"), deCODE genetics, ehf. ("Depositor") and PE Corporation
(NY) through its Applied Biosystems Group ("Preferred Beneficiary"), who
collectively may be referred to in this Agreement as "the parties."
A. Depositor and Preferred Beneficiary have entered or will enter into a
license agreement, development
_____________
dt 1323125
;
| PE Corporation
|
| Preview
Full Doc
| 2001 |
Joint Development and Commercialization Agreement
Joint Development and Commercialization Agreement (196K)
Doc #304250: Click preview link for longer preview.
JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Joint Development and Commercialization Agreement ("Agreement") dated as of
the 16th day of July, 2001 ("Effective Date") is by and between deCODE GENETICS,
ehf., an Icelandic corporation, located at Hlioarsmari 15, 200 Kopavogur,
Iceland ("deCODE"), and PE CORPORATION (NY), a New York corporation, through its
Applied Biosystems Group, located at 850 Lincoln Centre Drive, Foster City, CA
94404 ("ABG").
BACKGROUND
A. ABG has certain skills, proprietary technology and know-how
related to the development of bioanalytical instrumentation systems including
associated software and reagents, and the marketing, sales and support of
products incorporating such systems.
B. deCODE has certain skills, proprietary technology and know-how
related to the operation and management of large scale genotyping facilities,
including particular expertise in the development of software to manage and
analyze data generated by such facilities.
C. deCODE and ABG desire to form a joint development and
commercialization program with the objective of developing and commercializing
software products for the collection, organization and analysis of genotyping
information subject to the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing premises and the
mutual promises and covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, do hereby agree as follows:
AGREEMENT
1. DEFINITIONS
1.1 "ABG Instrumentation" means instrumentation developed or
marketed by ABG.
1.2 "ABG API" means APIs provided to deCODE by ABG that provide
access to the functional capabilities within ABG software,
including, but not limited to, the ABG LIMS System, which is
necessary to access data necessary for the operation of a
Collaboration Product, including, but not limited to: sample
management, container management, location management,
genotype marker management, genotype assay management, and
genotype results management.
1
{PAGE} 3
EXECUTION COPY
1.3 "ABG LIMS System" means LIMS systems developed or marketed by
ABG, including but not limited to SQL*LIMS, SQL*GT, and Life
Science LIMS.
1.4 "Administration Cost" means salaries and overhead of general
management, finance, human resources, and legal functions as
calculated as a percentage of sales based on the current
fiscal year allocations using a Party's customary practices
and procedures in accordance with United States generally
accepted accounting principles ("GAAP").
1.5 "Affiliate" means
(A) an organization of which 50% or more of the voting
stock or participating profit interest is controlled
or owned directly or indirectly by either Party;
(B) an organization that directly or indirectly owns or
controls 50% or more of the voting stock of a Party;
(C) an organization, the majority ownership of which is
directly or indirectly common to the majority
ownership of either Party; or
(D) an organization under (A), (B), or (C) immediately
above in which the amount of the ownership is less
than 50% and that amount is the maximum amount
permitted by law.
1.6 "Algorithm Development" means the invention or refinement of
logical operations (numeric, textual, graphic, or otherwise)
into a form expressable in the form of software code.
1.7 "API" means an application programming interface through which
multiple elements of software (e.g., Components) can
communicate, exchange information, and work together,
including a documented description of the use of the API and
the behavior of the multi-element system when the API is
invoked.
1.8 "Background ABG Intellectual Property" means all Intellectual
Property Rights that (A) are owned by, either partially or
wholly, or licensed to, or otherwise controlled by, ABG as of
the Effective Date; or (B) become owned by, either partially
or wholly, or licensed to, or otherwise controlled by, ABG,
during the term of this Agreement, but that do not arise out
of work performed under this Agreement, and which relate to
ABG LIMS Systems used in the Genotyping Field; provided,
however, this definition expressly excludes any Intellectual
Property Rights relating to instrumentation or reagents..
2
{PAGE} 4
EXECUTION COPY
1.9 "Background deCODE Intellectual Property" means all
Intellectual Property Rights that (A) are owned by, either
partially or wholly, or licensed to, or otherwise controlled
by, deCODE as of the Effective Date, which relate to the
Genotyping Field; or (B) become owned by, either partially or
wholly, or licensed to, or otherwise controlled by, deCODE,
during the term of this Agreement, but that do not arise out
of work performed under this Agreement and which relate to the
Genotyping Field.
1.10 "Collaboration ABG Intellectual Property" means all
Intellectual Property Rights arising out of work performed
under this Agreement that are conceived solely by one or more
employees or agents of ABG or its Affiliates.
1.11 "Collaboration deCODE Intellectual Property" means all
Intellectual Property Rights arising out of work performed
under this Agreement that are conceived solely by one or more
employees or agents of deCODE or its Affiliates.
1.12 "Collaboration Joint Intellectual Property" means all
Intellectual Property Rights arising out of work performed
under this Agreement, that are jointly conceived by one or
more employees or agents of deCODE or its Affiliates, and by
one or more employees or agents of ABG or its Affiliates.
1.13 "Collaboration Product" means products developed under the
Joint Development Program and incorporating Existing deCODE
Genotyping Software or New deCODE Genotyping Software for use
in the Genotyping Field in conjunction with ABG APIs and other
ABG software, including any Improvement Product developed
pursuant to Section 3.5.
1.14 "Collaboration Profit" means [CONFIDENTIAL TREATMENT
REQUESTED] provided however, in no event will the deductions
for [CONFIDENTIAL TREATMENT REQUESTED] For avoidance of doubt,
Development Funding paid to deCODE by ABG pursuant to Sections
3.9 and 5.1 will not be deducted from Collaboration Revenue
for purposes of computing Collaboration Profit.
1.15 "Collaboration Revenue" means all revenue received by ABG in
connection with the sale of a software product incorporating a
Collaboration Product, including software, informatics
services, and informatics support, including revenues
collected under Software Maintenance Plans and Custom
Maintenance Plans. Collaboration Revenue would exclude any
revenues received by ABG as a result of the sale by ABG of
instrument or reagent products.
3
{PAGE} 5
EXECUTION COPY
1.16 "Componentization" means the separation and isolation of
elements of a larger software system into discrete and
separately deployable units. These Components may be dependent
on other Components or applications for data, but the
Components do not make assumptions about the specific source
of these data, so long as the data are formatted properly
according to the Component's APIs.
1.17 "Components" shall have the meaning set forth at Exhibit A.
1.18 "Confidential Information" means confidential knowledge,
know-how, practices, processes, equipment, software,
algorithms and formulas, sources codes, product designs,
sales, cost and other financial statements and financial
projections; product development and business plans, marketing
and distribution plans or other information that:
(A) is disclosed by a Party in a tangible form and is
304250
|
Applied
As referenced in this Joint Development and Commercialization Agreement:
Applied Biosystems Group, – Effective Date") is by and between deCODE GENETICS,
ehf., an Icelandic corporation, located at Hlioarsmari 15, 200 Kopavogur,
Iceland ("deCODE"), and PE CORPORATION (NY), a New York corporation, through its
Applied Biosystems Group, located at 850 Lincoln Centre Drive, Foster City, CA
94404 ("ABG").
BACKGROUND
A. ABG has certain skills, proprietary technology and know-how
related to the development of bioanalytical instrumentation
_____________
APPLIED BIOSYSTEMS GROUP
– Page Follows]
41
{PAGE} 43
EXECUTION COPY
The Parties , through their authorized officers, have executed this Agreement as
of the Effective Date.
deCODE GENETICS, ehf. PE CORPORATION (NY), THROUGH
ITS APPLIED BIOSYSTEMS GROUP
By: /s/ Kari Stefansson By: /s/ Michael W. Hunkapiller
-------------------------------- ---------------------------
Name: Kari Stefansson Name: Michael W. Hunkapiller
-------------------------------- -------------------------
Title: CHIEF EXECUTIVE OFFICER Title: Senior Vice President
-------------------------------- and President Applied
Biosystems Group
------------------------
_____________
Applied
Biosystems Group
– ITS APPLIED BIOSYSTEMS GROUP
By: /s/ Kari Stefansson By: /s/ Michael W. Hunkapiller
-------------------------------- ---------------------------
Name: Kari Stefansson Name: Michael W. Hunkapiller
-------------------------------- -------------------------
Title: CHIEF EXECUTIVE OFFICER Title: Senior Vice President
-------------------------------- and President Applied
Biosystems Group
------------------------
Date: July 16, 2001 Date: July 16, 2001
-------------------------------- -------------------------
42
{PAGE} 44
EXECUTION COPY
EXHIBIT A
SOFTWARE COMPONENTS
The following describes the division of Existing deCODE Genotyping Software into
independently
_____________
Applied Biosystems Group – B
PREFERRED SOFTWARE ESCROW AGREEMENT
Account Number
------------------------
This Agreement is effective __________________, 2001 among DSI Technology Escrow
Services, Inc. ("DSI"), deCODE genetics, ehf. ("Depositor") and PE Corporation
(NY) through its Applied Biosystems Group ("Preferred Beneficiary"), who
collectively may be referred to in this Agreement as "the parties."
A. Depositor and Preferred Beneficiary have entered or will enter into a
license agreement, development
_____________
dt 1323131
;
| |
| Preview
Full Doc
| 2002 |
Development and Commercialization Agreement
Development and Commercialization Agreement (321K)
Doc #1134121: Click preview link for longer preview.
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
-------------------------------------------------------------------------------- . . .
1134121
|
ACLARA
As referenced in this Development and Commercialization Agreement:
ACLARA BIOSCIENCES, INC. – txt
<DESCRIPTION>DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
<TEXT>
<PAGE>
EXHIBIT 10.29
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated
_____________
ACLARA BioSciences,
Inc. – the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc. , a Delaware corporation, having a place of business at 1288 Pear Avenue,
Mountain View, CA 94043 ("ACLARA") (each a "PARTY;" together the "PARTIES").
BACKGROUND
A. TWT has technology and
_____________
ACLARA BioSciences, Inc. – following address or such other address as may from time to
time be designated to the other Party in writing in accordance with this Section
20.6:
If to: ACLARA
ACLARA BioSciences, Inc.
1288 Pear Avenue
Mountain View, CA 94043
Attn: President and CEO
Telefax: (650) 210-9271
-81-
<PAGE>
CONFIDENTIAL
With a copy to:
Vice President, Legal Affairs
If
_____________
ACLARA BIOSCIENCES, INC. – same instrument.
[Intentionally Left Blank]
-84-
<PAGE>
CONFIDENTIAL
IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Agreement.
THIRD WAVE TECHNOLOGIES, INC. ACLARA BIOSCIENCES, INC.
("TWT") ("ACLARA")
<TABLE>
<CAPTION>
<S> <C> <C> <C>
By: /s/ Ian B. Edvalson By: /s/ Philip A.
_____________
dt 1453660
;
ACLARA
As referenced in this Development and Commercialization Agreement:
ACLARA BIOSCIENCES, INC. – txt
<DESCRIPTION>DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
<TEXT>
<PAGE>
EXHIBIT 10.29
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated
_____________
ACLARA BioSciences,
Inc. – the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc. , a Delaware corporation, having a place of business at 1288 Pear Avenue,
Mountain View, CA 94043 ("ACLARA") (each a "PARTY;" together the "PARTIES").
BACKGROUND
A. TWT has technology and
_____________
ACLARA BioSciences, Inc. – following address or such other address as may from time to
time be designated to the other Party in writing in accordance with this Section
20.6:
If to: ACLARA
ACLARA BioSciences, Inc.
1288 Pear Avenue
Mountain View, CA 94043
Attn: President and CEO
Telefax: (650) 210-9271
-81-
<PAGE>
CONFIDENTIAL
With a copy to:
Vice President, Legal Affairs
If
_____________
ACLARA BIOSCIENCES, INC. – same instrument.
[Intentionally Left Blank]
-84-
<PAGE>
CONFIDENTIAL
IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Agreement.
THIRD WAVE TECHNOLOGIES, INC. ACLARA BIOSCIENCES, INC.
("TWT") ("ACLARA")
<TABLE>
<CAPTION>
<S> <C> <C> <C>
By: /s/ Ian B. Edvalson By: /s/ Philip A.
_____________
dt 1463891
;
|
Third Wave
As referenced in this Development and Commercialization Agreement:
THIRD WAVE TECHNOLOGIES, – 8
<FILENAME>dex1029.txt
<DESCRIPTION>DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
<TEXT>
<PAGE>
EXHIBIT 10.29
CONFIDENTIAL
--------------------------------------------------------------------------------
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
THIRD WAVE TECHNOLOGIES, INC.
AND
ACLARA BIOSCIENCES, INC.
DATED OCTOBER 24, 2001
--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the
_____________
Third Wave Technologies, – vi-
<PAGE>
CONFIDENTIAL
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Development and Commercialization Agreement (the "AGREEMENT"),
effective as of October 24, 2001 (the "EFFECTIVE DATE"), is made by and between
Third Wave Technologies, Inc., a Delaware corporation, having a place of
business at 502 S. Rosa Road, Madison, WI 53719 ("TWT"), and ACLARA BioSciences,
Inc., a Delaware corporation, having a place of
_____________
Third Wave Technologies, – Pear Avenue
Mountain View, CA 94043
Attn: President and CEO
Telefax: (650) 210-9271
-81-
<PAGE>
CONFIDENTIAL
With a copy to:
Vice President, Legal Affairs
If to: TWT
Third Wave Technologies, Inc.
502 South Rosa Road
Madison, WI 53719
Attn: President
Telefax: (608) 273-8618
With a copy to:
Wilson Sonsini Goodrich & Rosati
650 Page Mill Road
Palo Alto,
_____________
THIRD WAVE TECHNOLOGIES, – constitute one and the same instrument.
[Intentionally Left Blank]
-84-
<PAGE>
CONFIDENTIAL
IN WITNESS WHEREOF, the Parties hereto have caused their duly
authorized representatives to execute this Agreement.
THIRD WAVE TECHNOLOGIES, INC. ACLARA BIOSCIENCES, INC.
("TWT") ("ACLARA")
<TABLE>
<CAPTION>
<S> <C> <C> <C>
By: /s/ Ian B. Edvalson
_____________
Third Wave Technologies, – and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
<PAGE>
CONFIDENTIAL
EXHIBIT 1.69
TWT MARKS
o Third Wave Technologies, Inc.
o Invader(R)
o Cleavase(R)
<PAGE>
CONFIDENTIAL
EXHIBIT 3.1
INITIAL DEVELOPMENT PLAN AND BUDGET
INITIAL WORK PLAN
[ * ]
---------------------
[ * ] Certain information on this page has been
_____________
dt 1473232
|